Phase 3 Myasthenia Gravis Trial, Recruiting NCT07039916 Sponsor: Immunovant Sciences GmbH Condition: Myasthenia Gravis
Back to Myasthenia Gravis

Phase 3 Myasthenia Gravis Trial, Recruiting

NCT07039916
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are able to understand what the trial involves, are willing to sign a consent form, and can follow the trial procedures
  • You have been diagnosed with mild to severe myasthenia gravis (MG), falling into a specific category (Class II, III, or IVa) as assessed at your screening appointment
  • Your MG symptoms significantly affect your daily life, as measured by a standard MG scoring tool (a score of 6 or higher), both at your screening appointment and at the start of the trial

Who may not be able to join:

  • You have had a severe MG episode (called a "myasthenic crisis," where breathing or swallowing became seriously affected) within the last 12 weeks before your screening appointment
  • You have had surgery to remove your thymus gland less than 6 months before your screening appointment, or you are planning to have that surgery while the trial is ongoing
  • You currently have an active or untreated tumour of the thymus gland (called a thymoma)

Please note: There are additional eligibility requirements not listed here that the trial team will assess.


Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 18007970414

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Immunovant Sciences GmbH
Registry
ClinicalTrials.gov
Start date
27 May 2025
Est. completion
1 December 2027

Where this trial is recruiting

🇦🇷 Argentina 🇨🇿 Czechia 🇩🇰 Denmark 🇬🇪 Georgia 🇩🇪 Germany 🇬🇷 Greece 🇭🇺 Hungary 🇮🇹 Italy 🇵🇱 Poland 🇷🇴 Romania 🇷🇸 Serbia 🇪🇸 Spain 🇬🇧 United Kingdom 🇺🇸 United States

Primary endpoints

Change from Baseline in MG-ADL Score for Antibody-positive Participants

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov